Last updated
Sana Biotechnology, Inc.: Capital Raising
Schedule 13G filing indicates potential significant ownership change or investment activity
Source: SEC EDGAR — Current Filings
The leadership read
Fresh capital usually broadens biotech & pharma leadership bench strength — scale, go-to-market and operational depth — rather than any single appointment.
Market context: This lands while the Talent Market Index reads 105.8 (Hot) — down 2.4 versus the prior month — and Americas signal share is rising (+2.4pts).
Sana Biotechnology, Inc.: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies.
MitchelLake in this thematic
More signals across Biotech & Pharma
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Capital Raising · Americas
Twist Bioscience →Twist Bioscience filed an omnibus shelf registration and registered a $200M at-the-market (ATM) follow-on equity offering of common shares in June 2026.
Partnership · Americas
Bristol Myers Squibb →Bristol Myers Squibb announced a partnership with Nvidia to build an advanced AI supercomputer system for drug discovery and development, positioning it as the most advanced and energy-efficient system in biopharma.
Product Launch · Americas
Boehringer Ingelheim →Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.
Ma Activity · Americas
Biogen →Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.
Intelligence powered by Autonodal ↗